Tesamorelin

At a glance

Standard Protocol

Alternative: Split Dosing

GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (GHRH); route Subcutaneous; timing Pre-Bed Fasted. Label/trial anchors carry more weight than forum-style escalation. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. GH-axis stacking should be filtered for total IGF-1/glucose burden, not just expected synergy.

• Injection site erythema (redness): most distinctive adverse effect of tesamorelin vs. other GHRH analogs; more frequent and pronounced than with CJC-1295 or sermorelin; reported in approximately 6.4-25% of subjects in FDA trial data.
• Injection site pain and irritation: discomfort at administration site; rotate sites to minimize.
• Water retention and peripheral edema: GH-mediated sodium and fluid retention; more prominent in the first 4 weeks.
• Joint pain and arthralgia: GH-related periarticular fluid accumulation; common.
• Joint stiffness: particularly wrists, hands, and knees.
• Myalgia (muscle pain): GH-mediated; typically transient.
• Tingling or numbness in extremities: paresthesia from GH-related fluid shifts.
• Carpal tunnel syndrome: GH-mediated median nerve compression; more likely at higher doses and in predisposed subjects.
• Mild to moderate blood sugar elevations: transient fasting glucose increases; monitor glycemic status throughout.
• Nausea: reported in phase 3 data.
• Vomiting: less common.
• Headache: vasodilation-related; transient.
• Fatigue: early-cycle adaptation.
• Dizziness.
• Elevated IGF-1: supraphysiologic IGF-1 levels possible at higher doses; monitor with blood work on extended cycles.
• Hypersensitivity reactions: urticaria, rash, pruritus, flushing; more commonly reported than with other GHRH analogs; likely related to the trans-3-hexenoic acid modification.
• Anaphylaxis: rare but documented.
• Injection site antibody formation: anti-tesamorelin antibodies develop in some subjects with prolonged use; may reduce efficacy.
• Pituitary downregulation: risk with cycles beyond 12 weeks without washout.

• Active malignancy of any type: GH and IGF-1 elevation accelerates tumor cell proliferation.
• History of malignancy: exercise caution; tesamorelin should not be initiated without careful oncology risk assessment.
• Disruption of the hypothalamic-pituitary axis: pituitary tumors, pituitary surgery, head trauma, cranial radiation, or hypopituitarism from any cause.
• Concurrent use with CJC-1295 No DAC, CJC-1295 DAC, sermorelin, or HGH 191aa: direct GHRH receptor redundancy and additive GH/IGF-1 overstimulation.
• Concomitant glucocorticoid therapy: inhibits GH secretion and IGF-1 production.
• Uncontrolled diabetes mellitus or significant insulin resistance: tesamorelin produces the most pronounced blood glucose effects of the GHRH analogs in this database.
• Diabetic ketoacidosis.
• Known hypersensitivity to tesamorelin, mannitol (excipient), or any formulation components.
• Pregnancy: teratogenicity not established; avoid.
• Breastfeeding: safety not established; avoid.
• Pediatric use with open growth plates: risk of disproportionate bone growth stimulation.
• Severe carpal tunnel syndrome: GH-mediated fluid retention worsens nerve compression.
• Active proliferative or severe non-proliferative diabetic retinopathy: IGF-1 elevation may worsen retinal vasculopathy.

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
• https://pubmed.ncbi.nlm.nih.gov/?term=Tesamorelin
• https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=tesamorelin